Semaglutide cardiovascular risk has become an important topic in diabetes and metabolic research. The SUSTAIN-6 study evaluated cardiovascular outcomes in patients with type 2 diabetes and provided important insights into major adverse cardiovascular events associated with semaglutide treatment.
Once-weekly injection of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue manufactured by Novo Nordisk, significantly reduced the risk of major adverse cardiovascular events when compared with usual care in patients with type 2 diabetes, according to the results of the SUSTAIN-6 study.
Study Background
The SUSTAIN-6 trial enrolled 3,297 randomized subjects. Most participants had established cardiovascular disease, chronic kidney disease, or both.
Researchers evaluated semaglutide in addition to standard care and compared outcomes with placebo plus standard care. The study followed participants for a median period of 2.1 years.
Treatment with semaglutide reduced the combined risk of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death by 26% compared with placebo. The primary outcome occurred in 8.9% of patients treated with placebo and 6.6% of patients treated with semaglutide.
The study was presented by Steven Marso, MD, at the European Association for the Study of Diabetes meeting in Munich, Germany. The findings were also published in the New England Journal of Medicine.
Primary Cardiovascular Outcomes
Researchers estimated that approximately 45 patients would need to receive semaglutide treatment over 24 months to prevent one primary endpoint event.
The study also reported an increase in complications related to retinopathy. These complications occurred in 3.0% of semaglutide-treated patients compared with 1.8% of patients receiving placebo.
At the same time, investigators observed a reduction in the risk of new or worsening nephropathy among patients receiving semaglutide.
The SUSTAIN-6 study remains one of the most frequently cited investigations regarding semaglutide cardiovascular risk and cardiovascular outcomes in patients with type 2 diabetes.
Stroke and Kidney Findings
Among the components of the primary endpoint, the reduction in nonfatal stroke was statistically significant.
Researchers reported that semaglutide reduced the risk of nonfatal stroke by 39% compared with placebo. The rate of nonfatal stroke was 1.6% in the semaglutide group and 2.7% in the placebo group.
The incidence of nonfatal myocardial infarction was also lower in patients receiving semaglutide. Rates were 2.9% in the semaglutide group and 3.9% in the placebo group. However, this difference did not reach statistical significance.
Investigators reported no significant effect on cardiovascular mortality during the study period.
These findings contributed significantly to ongoing discussions surrounding semaglutide cardiovascular risk and long-term cardiovascular outcomes.
Comparison with Other Cardiovascular Studies
The SUSTAIN-6 trial is often discussed alongside other major cardiovascular outcome studies involving glucose-lowering therapies.
Results from the LEADER study, which evaluated liraglutide (Victoza), showed that the drug significantly reduced the risk of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke by 13% compared with placebo.
The LEADER study also reported a 15% reduction in all-cause mortality and a 22% reduction in cardiovascular mortality among liraglutide-treated patients. Unlike semaglutide, which is administered once weekly, liraglutide is given as a once-daily subcutaneous injection.
Researchers have also compared SUSTAIN-6 with the EMPA-REG OUTCOME trial evaluating empagliflozin (Jardiance). In that study, empagliflozin reduced the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with type 2 diabetes.
Researchers continue to evaluate semaglutide cardiovascular risk across different patient populations and clinical settings.
Future Perspectives
SUSTAIN-6 was designed to meet cardiovascular safety requirements established by the U.S. Food and Drug Administration following concerns surrounding earlier diabetes therapies.
The study helped demonstrate that semaglutide did not result in an unacceptable increase in cardiovascular risk and provided important evidence regarding cardiovascular safety.
Additional cardiovascular outcome studies involving GLP-1 receptor agonists, including EXSCEL with exenatide and REWIND with dulaglutide, have further expanded scientific understanding in this field.
As research continues to evolve, semaglutide cardiovascular risk remains an important topic within metabolic, cardiovascular, and diabetes research. Future studies may provide additional insights into long-term cardiovascular outcomes and the broader role of GLP-1 receptor agonists in modern medicine.